Preserving hearing is our mission
Oricula Therapeutics, LLC, is working to develop the first medication approved to prevent hearing loss. Our first product will prevent hearing loss as a frequent side effect of an important class of antibiotic, aminoglycosides. Oricula research is progressing towards a FDA Investigational New Drug (IND) filing for this product. Reducing or eliminating hearing loss as a side effect of aminoglycoside therapy would allow broader worldwide use of these important antibiotics for the treatment of life-threatening bacterial infections, such as endocarditis, neonatal septicemia and multi-drug resistant tuberculosis.